-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Intellia Therapeutics, Raises Price Target to $29

Benzinga·03/03/2026 16:16:16
Listen to the news
Leerink Partners analyst Mani Foroohar maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price target from $27 to $29.